WO2003057215A1 - Neurotrophic factor production/secretion accelerator - Google Patents

Neurotrophic factor production/secretion accelerator Download PDF

Info

Publication number
WO2003057215A1
WO2003057215A1 PCT/JP2002/013654 JP0213654W WO03057215A1 WO 2003057215 A1 WO2003057215 A1 WO 2003057215A1 JP 0213654 W JP0213654 W JP 0213654W WO 03057215 A1 WO03057215 A1 WO 03057215A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
neurotrophic factor
factor production
group
secretion accelerator
Prior art date
Application number
PCT/JP2002/013654
Other languages
French (fr)
Japanese (ja)
Inventor
Masatoshi Hazama
Norihisa Iwakami
Takeshi Miyazaki
Nozomu Sakai
Tsuyoshi Maekawa
Yu Momose
Toru Kawamura
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Priority to AU2002367426A priority Critical patent/AU2002367426A1/en
Publication of WO2003057215A1 publication Critical patent/WO2003057215A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A neurotrophic factor production/secretion accelerator containing a compound represented by the general formula (I): (I) [wherein one of R1 and R2 represents hydrogen or a substituent and the other represents an optionally substituted cyclic group; W represents a bond or divalent aliphatic hydrocarbon group; and Y represents a group represented by the formula -OR3 (R3 represents hydrogen or an optionally substituted hydrocarbon group, optionally substituted heterocyclic group, or optionally substituted acyl) or optionally esterified or amidated carboxy], a salt of the compound, or a prodrug of either. The compound represented by the general formula (I) has excellent activity and is lowly toxic.
PCT/JP2002/013654 2001-12-28 2002-12-26 Neurotrophic factor production/secretion accelerator WO2003057215A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002367426A AU2002367426A1 (en) 2001-12-28 2002-12-26 Neurotrophic factor production/secretion accelerator

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001401380 2001-12-28
JP2001-401380 2001-12-28

Publications (1)

Publication Number Publication Date
WO2003057215A1 true WO2003057215A1 (en) 2003-07-17

Family

ID=19189767

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/013654 WO2003057215A1 (en) 2001-12-28 2002-12-26 Neurotrophic factor production/secretion accelerator

Country Status (2)

Country Link
AU (1) AU2002367426A1 (en)
WO (1) WO2003057215A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502817A (en) * 2003-08-20 2007-02-15 イーライ リリー アンド カンパニー Compounds, methods and formulations for oral delivery of glucagon-like peptide (GLP) -1 compounds or melanocortin 4 receptor (MC4) agonist peptides
US7470715B2 (en) 2005-12-22 2008-12-30 Pfizer Inc. Estrogen modulators
US8304438B2 (en) 2006-12-20 2012-11-06 Sanofi Heteroarylacrylamides and their use as pharmaceuticals
US8552039B2 (en) 2003-08-20 2013-10-08 Emisphere Technologies, Inc. Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide
US8604069B2 (en) 2011-04-28 2013-12-10 Japan Tobacco Inc. Amide compound and medicinal use thereof
CN113480489A (en) * 2021-08-19 2021-10-08 贵州大学 Isoxazole biphenyl compound and preparation method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517354A (en) * 1991-07-03 1993-01-26 Nichiban Co Ltd Percutaneous absorption preparation containing isoxazole derivative
JPH08175992A (en) * 1994-12-21 1996-07-09 Sagami Chem Res Center Agent for promoting production of nerve growth factor and condensed ring type oxazole compound
WO2001014372A2 (en) * 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent
WO2002040458A1 (en) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Isoxazole derivatives
JP2003081831A (en) * 2001-06-26 2003-03-19 Takeda Chem Ind Ltd TGF-beta SUPERFAMILY PRODUCTION/SECRETION PROMOTER

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517354A (en) * 1991-07-03 1993-01-26 Nichiban Co Ltd Percutaneous absorption preparation containing isoxazole derivative
JPH08175992A (en) * 1994-12-21 1996-07-09 Sagami Chem Res Center Agent for promoting production of nerve growth factor and condensed ring type oxazole compound
WO2001014372A2 (en) * 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent
WO2002040458A1 (en) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Isoxazole derivatives
JP2003081831A (en) * 2001-06-26 2003-03-19 Takeda Chem Ind Ltd TGF-beta SUPERFAMILY PRODUCTION/SECRETION PROMOTER

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH, vol. 18, no. 3, 1993, pages 201 - 208 *
DATABASE MEDLINE [online] "Differential regulation of the expression of nerve growth factor, brain-derived neurotrophic factor and neurotrophin-3 after excitotoxicity in a rat model of Huntington's disease", XP002965288, accession no. STN Database accession no. 1999167108 *
DATABASE MEDLINE [online] "Glutamate receptor agonists enhance the expression of BDNF mRNA in cultured cerebellar granule cells", XP002965289, accession no. STN Database accession no. 93268074 *
KATOH-SEMBA R. ET AL.: "Induction of brain-derived neurotrophic factor by convulsant drugs in the rat brain: involvement of region-specific voltage-dependent calcium channels", JOURNAL OF NEUROCHEMISTRY, vol. 77, no. 1, 2000, pages 71 - 83, XP002965287 *
NEUROBIOLOGY OF DISEASE, vol. 5, no. 5, 1998, pages 357 - 364 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502817A (en) * 2003-08-20 2007-02-15 イーライ リリー アンド カンパニー Compounds, methods and formulations for oral delivery of glucagon-like peptide (GLP) -1 compounds or melanocortin 4 receptor (MC4) agonist peptides
US7947841B2 (en) 2003-08-20 2011-05-24 Emisphere Technologies, Inc. Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide
JP4754487B2 (en) * 2003-08-20 2011-08-24 エミスフィアー テクノロジーズ インコーポレイテッド Compounds, methods and formulations for oral delivery of glucagon-like peptide (GLP) -1 compounds or melanocortin 4 receptor (MC4) agonist peptides
US8546581B2 (en) 2003-08-20 2013-10-01 Emisphere Technologies, Inc. Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (Glp)-1 compound or a melanocortin-4 receptor (Mc4) agonist peptide
US8552039B2 (en) 2003-08-20 2013-10-08 Emisphere Technologies, Inc. Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide
US8765796B2 (en) 2003-08-20 2014-07-01 Emisphere Technologies, Inc. Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide
US7470715B2 (en) 2005-12-22 2008-12-30 Pfizer Inc. Estrogen modulators
US8304438B2 (en) 2006-12-20 2012-11-06 Sanofi Heteroarylacrylamides and their use as pharmaceuticals
US8604069B2 (en) 2011-04-28 2013-12-10 Japan Tobacco Inc. Amide compound and medicinal use thereof
CN113480489A (en) * 2021-08-19 2021-10-08 贵州大学 Isoxazole biphenyl compound and preparation method and application thereof

Also Published As

Publication number Publication date
AU2002367426A1 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
AU3461697A (en) Heterocyclic compounds, their production and use
WO2002100812A1 (en) Carboxylic acid derivative and salt thereof
WO2004024777A8 (en) Hydroxyalkyl starch derivatives
WO2003006425A3 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
EP1394147A4 (en) Carboxylic acid derivative and medicine comprising salt or ester of the same
RS51444B (en) Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CA2173150A1 (en) Novel peptide derivatives
WO2002076995A3 (en) 2-amino-propanol derivatives
CA2418770A1 (en) Acylacetonitrile compound, process for preparation thereof, and miticide containing the same
WO2003046034A3 (en) Improved synthesis of polyanhyrides
EP1582521A4 (en) Fused furan compound
WO1999009965A3 (en) Anti-inflammatory agent
EP1291344A4 (en) Rice blast control agents
WO2003035620A1 (en) Bicyclic compound
MXPA05013631A (en) Heterocyclic methyl sulfone derivative.
WO2003004497A1 (en) Novel heterocyclic compound
WO2002000638A8 (en) Substituted phthalides as anti-convulsive drugs
WO2003057215A1 (en) Neurotrophic factor production/secretion accelerator
EP1550651A4 (en) Glycerol derivative
WO2003035650A1 (en) Entry inhibitor
DE60230781D1 (en) Reverse hydroxamsäurederivate
EP1661898A4 (en) Bicyclic piperazine compound and use thereof
EP1346994A4 (en) Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds
EP1310490A4 (en) Gpr14 antagonist
CA2376691A1 (en) Antipsychotic cyclic n-aralkylamines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP